Jul. 16 2024
Source Page: Freedom of Information responses from the MHRA: 22 January 2024Found: 384.5 (299.6) 0 - 1161 Drug ineffective 27 (7.1%) 27 (12.1%) 433.4 (267.9) 0 - 1111 Infections
Jan. 17 2024
Source Page: Freedom of Information responses from the MHRA - week commencing 31 October 2022Found: signs and symptoms of CD, surgery may be required to remove the damaged portion of the digestive tract
Sep. 19 2024
Source Page: Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]Found: infection 1 (10.0) 1 (12.5) 0 Urinary tract infection 1 (10.0) 2 (25.0) 0 Vascular device infection
Aug. 20 2008
Source Page: Report to Ministers from The Department of Health Steering Group on the Statutory Regulation of Practitioners of Acupuncture, Herbal Medicine, Traditional Chinese Medicine and Other Traditional Medicine Systems Practised in the UK. 162 p.Found: preparations such as kalamegha (Andrographis paniculata ) for the treatment of upper respiratory infections
Nov. 11 2009
Source Page: Emergency readmission rates: Further analysis. 50 p.Found: Readmissions after maternity and readmissions for patients in mental health specialties or with a diagnosis
Apr. 24 2024
Source Page: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableFound: r'/ 2135 7 'urinary tract cancer'.mp. o r 'urinary tract tumo?
Aug. 22 2024
Source Page: Risankizumab for treating moderately to severely active ulcerative colitisFound: Diagnosis: Ulcerative colitis.
Feb. 20 2008
Source Page: Immunisation against infectious diseases. 470 p.Found: In humans, anthrax can affect the skin and, rarely, the respiratory or gastro-intestinal tract.
Jun. 12 2024
Source Page: Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209Found: Diagnosis: Ulcerative colitis.
Jun. 12 2024
Source Page: Risankizumab for treating moderately to severely active ulcerative colitisFound: Diagnosis: Ulcerative colitis.